Selkirk Pharma, Inc., a private US pharmaceutical manufacturer specializing in filling and at the end of injectable drugs, including vaccines and biological therapy, announced the circulation of Clinfast today.™An example of a transit service aimed at providing assistance for biotechnology and pharmaceutical clinical stadiums with a rapid filling/termination procedure for supplies of clinical trials. By reducing production schedules while maintaining high quality standards, Clinfast faces a significant challenge faced by medicine manufacturers-the choice of filling/termination capacity in a market where small lots are often abandoned by larger contracts (CMOS) .
In the development of clinical drugs, time is everything. Delays in sterile filling/finishing may mean lost milestones and significant financial failures, “
Colleen Dixon, CEO, Selkirk Pharma
“Clinfast represents a significant progress in our ability to ensure that biotechnology and pharmaceutical companies can have access to high quality drug production that is needed-without standard waiting times. Our experienced team, best equipment in class and commitment In excellence they mean that our clients can trust us to help them stay on the right track and bring faster treatments for patients. “
A faster course to clinical trials without sacrificing quality
The traditional filling/finishing landscape has major obstacles for small volume projects, with periods of waiting ranging from 6 to 12 months for a available reception. Clinfast eliminates these delays by performing production procedures at the same time and utilizing a prepositional approach that rationalized each step – from union to final liberation. The Selkirk Pharma maintains on -the -spot ISO vial census, stations, filling complexes and publishers, reducing the delivery time required for supply materials. The company also offers flexibility to customers to incorporate materials provided by the client aligned with the clinfast process.
Basic advantages of Clinfast:
- Rapid recovery: Provides clinical trial materials in a fraction of time required by larger CMO.
- Batch sizes up to 10,000 vials: Ideal for vials filled with liquids used in phase 1 and 2 tests.
- High Performance Editing: The state-of-the-art equipment minimizes line loss and ensures consistent returns with complete returns.
- Care: capable of supporting customers beyond clinical trials with commercial scale capacity.
With Clinfast, Selkirk Pharma provides a special solution to medicine manufacturers to satisfy critical clinical schedules. The approach based on the company’s risks prioritizes efficiency without ending quality, ensuring that each project receives the attention it deserves.
